Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | PLAU | P00749 | 1/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | LIPE | Q05469 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11495942 | 0.80 | ALDH1A1 (0.40) | TDP1MAPTTSHRRAB9AHTT | |
| SCHEMBL23182899 | 0.78 | ALDH1A1 (0.54) | TDP1KMT2AMEN1MAPTTSHR | |
| SCHEMBL3562724 | 0.78 | KDM4E (0.54) | TDP1KMT2AMEN1MAPTTSHR | |
| SCHEMBL10265614 | 0.78 | ALDH1A1 (0.49) | KMT2AMEN1MAPTTSHRRAB9A | |
| SCHEMBL4634579 | 0.77 | LIPE (0.47) | TDP1KMT2AMEN1TSHRRAB9A | |
| SCHEMBL31723848 | 0.76 | TDP1 (0.46) | TDP1MAPTTSHRPLAUPTGDR2 | |
| SCHEMBL22588560 | 0.76 | KMT2A (0.49) | TDP1KMT2AMEN1MAPTTSHR | |
| SCHEMBL29760620 | 0.76 | KMT2A (0.49) | TDP1KMT2AMEN1MAPTTSHR | |
| SCHEMBL11868262 | 0.74 | ALDH1A1 (0.48) | TDP1KMT2AMEN1MAPTTSHR | |
| SCHEMBL12015658 | 0.74 | CXCR1 (0.47) | KMT2AMEN1MAPTHTTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114401952-A | Substituted cycloalkyl compounds as modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2022-04-26 | — | — | CN | disclosed |
| EP-3962899-A1 | SUBSTITUTED CYCLOLAKYLS AS MODULATORS OF THE INTEGRATED STRESS PATHWAY | Calico Life Sciences LLC (US) | 2022-03-09 | — | — | EP | disclosed |
| US-20210093619-A1 | Chemical Compounds as ATF-4 Pathway Inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-04-01 | — | — | US | disclosed |
| CN-111757739-A | Integrated stress pathway inhibitors | 普拉西斯生物技术有限责任公司 | 2020-10-09 | — | — | CN | disclosed |
| CN-110730777-A | Chemical compounds as inhibitors of the ATF4 pathway | 葛兰素史密斯克莱知识产权发展有限公司 | 2020-01-24 | — | — | CN | disclosed |
| US-8603755-B2 | Resistance to auxinic herbicides | DOW AGROSCIENCES, LLC. (US) | 2013-12-10 | — | — | US | disclosed |
| US-8535893-B2 | Resistance to auxinic herbicides | AGRIGENETICS, INC. (US) | 2013-09-17 | — | — | US | disclosed |
| US-8535893-B2 | Resistance to auxinic herbicides | AGRIGENETICS, INC. (US) | 2013-09-17 | — | — | US | disclosed |
| US-8535893-B2 | Resistance to auxinic herbicides | AGRIGENETICS, INC. (US) | 2013-09-17 | — | — | US | disclosed |
| US-20120064539-A1 | RESISTANCE TO AUXINIC HERBICIDES | AGRIGENETICS, INC. | 2012-03-15 | — | — | US | disclosed |
| US-20110016590-A1 | RESISTANCE TO AUXINIC HERBICIDES | AGRIGENETICS, INC. | 2011-01-20 | — | — | US | disclosed |
| US-20110016590-A1 | RESISTANCE TO AUXINIC HERBICIDES | AGRIGENETICS, INC. | 2011-01-20 | — | — | US | disclosed |
| US-20110016590-A1 | RESISTANCE TO AUXINIC HERBICIDES | AGRIGENETICS, INC. | 2011-01-20 | — | — | US | disclosed |
| US-20110016591-A1 | RESISTANCE TO AUXINIC HERBICIDES | AGRIGENETICS, INC. | 2011-01-20 | — | — | US | disclosed |
| US-20110016591-A1 | RESISTANCE TO AUXINIC HERBICIDES | AGRIGENETICS, INC. | 2011-01-20 | — | — | US | disclosed |
| US-7820883-B2 | transgenic plant having increased resistance to a picolinate auxin herbicide; has inhibited expression of the wild-type AFB5 gene | DOW AGROSCIENCES LLC (US) | 2010-10-26 | — | — | US | disclosed |
| US-7820883-B2 | transgenic plant having increased resistance to a picolinate auxin herbicide; has inhibited expression of the wild-type AFB5 gene | DOW AGROSCIENCES LLC (US) | 2010-10-26 | — | — | US | disclosed |
| US-7820883-B2 | transgenic plant having increased resistance to a picolinate auxin herbicide; has inhibited expression of the wild-type AFB5 gene | DOW AGROSCIENCES LLC (US) | 2010-10-26 | — | — | US | disclosed |
| US-20070220629-A1 | transgenic plant having increased resistance to a picolinate auxin herbicide; has inhibited expression of the wild-type AFB5 gene | EXELIXIS PLANT SCIENCES, INC. | 2007-09-20 | — | — | US | disclosed |
| US-20070220629-A1 | transgenic plant having increased resistance to a picolinate auxin herbicide; has inhibited expression of the wild-type AFB5 gene | EXELIXIS PLANT SCIENCES, INC. | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110016590-A1 | RESISTANCE TO AUXINIC HERBICIDES | HSD17B4, AGXT, SGTA | TDP1 3783/4885KMT2A 2405/4885MEN1 4694/4885 |
| US-20210093619-A1 | Chemical Compounds as ATF-4 Pathway Inhibitors | ATF4, ATF1, XBP1 | TDP1 2441/4885KMT2A 2770/4885MEN1 4697/4885 |
| US-20110016591-A1 | RESISTANCE TO AUXINIC HERBICIDES | HSD17B4, AGXT, SGTA | TDP1 3783/4885KMT2A 2405/4885MEN1 4694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.